Effects of Menopausal Hormone Therapy on Uterine Fibroids in Women During Menopausal Transition Authors: Mengqi Huang, Jie Chen, Lin Gu, Yuxuan Yang, Pengfei Qin Published: 2026 ABSTRACT ObjectiveUterine fibroids are highly prevalent globally. However, evidence on the effects of menopausal hormone therapy (MHT) on fibroid growth during menopausal transition remains limited. This study explores the association between MHT and the size of uterine fibroids in women during the menopausal transition.MethodsThis retrospective observational study enrolled women during menopausal transition with uterine fibroids who received sequential menopausal hormone therapy (estradiol combined with dydrogesterone) at Nanjing Women and Children’s Healthcare Hospital from January 2016 to August 2023. Serial ultrasound examinations were performed to dynamically monitor changes in fibroid cross-sectional area during follow-up. A linear mixed-effects model was applied to explore the long-term impact of menopausal hormone therapy on fibroid size alterations over time. Furthermore, all adverse events occurring during hormone therapy were systematically recorded and summarized.ResultsA total of 83 patients were enrolled, with a maximum follow-up of 5 years post-treatment. Although statistically significant differences from baseline in fibroid cross-sectional area were observed during the first four years of follow-up, these changes were marginal and clinically unremarkable and undetectable at year 5. Most adverse events were transient and resolved spontaneously. The incidence rates of unexpected bleeding, breast discomfort and gastrointestinal symptoms were 18.07%, 10.84% and 2.41%, respectively.ConclusionFindings suggest that women during menopausal transition that receiving MHT may experience transient, minor changes in fibroid size. These changes are not considered clinically meaningful, and MHT exhibits an overall favorable safety profile for this group. With regular surveillance and use of the lowest effective dose, MHT represents a safe and practical therapeutic choice. Additional prospective investigations are needed to characterize the long-term dynamic changes of fibroids associated with MHT. Introduction Uterine fibroids, also known as uterine leiomyomas or myomas, are the most common benign gynecological tumors in women. They arise from uterine smooth muscle cells and contain abundant extracellular matrix components. Fibroids are hormonally responsive and typically enlarge during women’s reproductive years. They rarely develop before puberty and tend to regress after menopause.1–3 Common symptoms include heavy or prolonged menstrual bleeding, pelvic discomfort (pressure or pain), impaired fertility, bloating, urinary frequency and subsequent impacts on daily activities and psychological well-being.4,5 Black ethnicity, family history, parity, and obesity were also reported as risk factors for uterine fibroid.6 Uterine fibroids are highly prevalent, affecting approximately 70% of women of reproductive age. Around 30% experience clinically significant symptoms that require treatment. They represent a major public health concern and bring substantial medical, economic, and societal costs.2,3 Globally, the incidence and prevalence of uterine fibroids have increased over the past decade, with average annual percentage changes (AAPCs) of 0.27% in incidence and 0.078% in prevalence.2 In 2021, the incidence of uterine fibroids in China was estimated at 986.13 × 103 (95% UI: 712.46–1285.29 × 103), with an age-standardized incidence rate of 137.25 (101.86–177.94) per 100,000 population.7 In women with symptomatic uterine fibroids, available treatment strategies include medical, surgical, and radiologically guided approaches, each offering distinct advantages and limitations. Although several medical therapies have been introduced, gonadotropin releasing hormone (GnRH) agonists and selective progesterone receptor modulators (SPRMs) continue to be regarded as effective options for symptom relief in women who are approaching menopause.8,9 Furthermore, the Women’s Health Initiative (WHI) trial in 2002 reported an increased risk of cardiovascular events and breast cancer associated with combined conjugated equine estrogen and medroxyprogesterone acetate therapy, prompting ongoing concerns about hormone therapy safety.10 However, after extensive research and evaluation, medical scientists introduced the concept of “window of opportunity and minimum effective dose”,11 emphasizing the importance of individualized treatment for each patient. Currently, MHT is regarded as a comprehensive solution addressing multiple issues including vasomotor symptoms associated with postmenopausal estrogen deficiency.12,13 With the growing number of women presenting with clinical comorbidities and requiring MHT, the Chinese national menopause group emphasized as early as 2012 that uterine fibroids warranted cautious use of MHT but should not be considered as a contraindication.14 Despite all these concerns, many women in the menopausal transition and postmenopausal period still receive MHT to relieve bothersome menopausal symptoms, confirming its ongoing clinical value with prudent administration. However, other concerns persist whether patients with uterine fibroids should receive MHT, which drugs and routes of administration to choose, appropriate duration of therapy, and its potential effects on fibroid growth. In addition, while substantial evidence exists for the treatment and management of uterine fibroids in postmenopausal women,15–18 current data specific to women in the menopausal transition remain limited and inconsistent. To address this research gap, this retrospective observational study assessed alterations in uterine fibroid size pre- and post-MHT among women in the menopausal transition who had moderate to severe menopausal symptoms. Methods Eligibility Criteria for Patients This retrospective observational study included 45–55 year-old women in the menopausal transition with uterine fibroids. Eligible patients had a modified Kupperman score > 15 and received MHT at the Department of Gynecological Endocrinology, Nanjing Women and Children’s Healthcare Hospital from January 2016 to August 2023. According to the STRAW+10 staging system, the menopausal transition is specifically defined as the period characterized by changes in menstrual cycle length (a difference of ≥7 days between consecutive cycles) and/or episodes of amenorrhea lasting ≥60 days, corresponding to stages −2 and −1 of the STRAW+10 criteria. All patients had single or multiple uterine fibroids with a maximum diameter of <5.0 cm. Patients with submucosal fibroids, contraindications to hormone therapy, or those who had received hormone-related therapy within the past 3 months were excluded. During follow-up, if a patient experienced no withdrawal bleeding or expressed a preference to avoid menstruation, the regimen was switched from sequential MHT to either continuous combined therapy or tibolone. At this point, the patient’s further follow-up for the primary outcome of this study was terminated (Figure 1). This study was approved by the Ethical Review Committee of Nanjing Women and Children’s Healthcare Hospital (Approval no: 2023KY-111-01). Figure 1Follow-up of included patients.The flowchart outlines the follow-up process for participants diagnosed with uterine fibroids. Initially, 986 participants were screened, with 194 diagnosed and 134 aged between 45-55 years. After one year of sequential therapy initiation, 83 participants continued. By year two, 53 remained, with 30 lost due to reasons like fibroid enlargement concerns, surgery for endometrial polyps and other factors. In year three, 37 participants continued, with 16 lost due to treatment changes, surgery and other factors. By year four, 23 participants remained, with 14 lost due to treatment changes, newly detected breast cysts and other factors. Finally, in year five, 12 participants continued. The flowchart details reasons for discontinuation at each stage, including treatment changes and surgeries.A flowchart detailing participant follow-up in a uterine fibroids study over five years. Follow-up of included patients. Patient Assessment and Treatment Strategy According to the predefined inclusion and exclusion criteria, a total of 83 perimenopausal female patients with uterine fibroids who received menopausal hormone therapy were enrolled in the present study. Before treatment initiation, patients underwent a detailed evaluation that included medical history, gynecologic examination, cervical fluid-thin-layer cytology, human papillomavirus (HPV) testing, routine hematuria analysis, biochemical function tests, hepatobiliary–pancreatic–spleen color ultrasound, breast ultrasound, and bone density assessments. Transvaginal pelvic ultrasound was performed to measure the size of uterine fibroids (the measurement focused on the largest fibroid in cases of multiple fibroids). The cross-sectional area (cm2) of fibroid was calculated by using the formula: 0.78 (≈ π/4) × D1 (cm) ×D2 (cm) (where D1 and D2 are the perpendicular diameters of the fibroid at its maximum cross-sectional area). All the included patients received sequential estrogen and progesterone therapy, which was tailored according to individual responses at different stages. The oral estradiol dydrogesterone combination (1mg/10mg or 2mg/10mg) was used to stimulate the natural menstrual cycle. Statistical Methods A linear mixed-effects model (LMM) was used to analyze changes in uterine fibroid cross-sectional area before and after MHT initiation. The model included follow-up time point (pre-treatment to year 5) as the primary fixed effect, adjusted for baseline fibroid cross-sectional area, age, fibroid number (solitary/multiple), and prior myomectomy. A random intercept was specified for each participant. The LMM was implemented using the lme4 package in R software. All statistical analyses were performed using R software (R version 4.3.3, www.r-project.org). Two-sided tests were used, and P < 0.05 was considered statistically significant. Results Baseline Demographics of Patients This study included female patients aged 45–55 years (mean age: 48.58 ± 2.83 years), who were in the menopausal transition, diagnosed with uterine fibroids, and required MHT. Baseline characteristics are presented in Table 1.Table 1Basic Characteristics of PatientsCharacteristicsNumber of Patients (n/N, %)Age 45–50 years60/83 (72.29) 51–55 years23/83 (27.71)Number of fibroids Solitary57/83 (68.67) Multiple26/83 (31.32)Place of residence Urban56/83 (67.47) Rural27/83 (32.53)Parity 07/83 (8.43) ≥176/83 (91.57)History of chronic diseases Hypertension6/83 (7.23) Type 2 diabetes mellitus0/83 (0)Baseline laboratory parameters Fasting blood glucose3/83 (3.61) Total cholesterol14/83 (16.87) Triglyceride2/83 (2.41) Low-density lipoprotein7/83 (8.43) High-density lipoprotein2/83 (2.41)History of myomectomy Yes4/83 (4.82) None79/83 (95.18) Table 1Basic Characteristics of PatientsCharacteristicsNumber of Patients (n/N, %)Age 45–50 years60/83 (72.29) 51–55 years23/83 (27.71)Number of fibroids Solitary57/83 (68.67) Multiple26/83 (31.32)Place of residence Urban56/83 (67.47) Rural27/83 (32.53)Parity 07/83 (8.43) ≥176/83 (91.57)History of chronic diseases Hypertension6/83 (7.23) Type 2 diabetes mellitus0/83 (0)Baseline laboratory parameters Fasting blood glucose3/83 (3.61) Total cholesterol14/83 (16.87) Triglyceride2/83 (2.41) Low-density lipoprotein7/83 (8.43) High-density lipoprotein2/83 (2.41)History of myomectomy Yes4/83 (4.82) None79/83 (95.18) Basic Characteristics of Patients Adverse Reactions After MHT in Patients with Uterine Fibroids During Menopausal Transition Among the 83 patients receiving MHT, 15 (18.07%) experienced unexpected mild vaginal bleeding. Of these, 9 cases occurred within the first year of treatment, and 6 occurred during subsequent years, including 9 cases in year 1, 3 cases in year 2, and 3 cases in year 3. The etiology of bleeding was undocumented in most cases, and no recurrence was observed in the majority of patients. Notably, two patients with first-year bleeding developed recurrent bleeding and were lost to follow-up after one year of treatment. One patient who experienced bleeding in the third year had recurrent symptoms and underwent hysteroscopy; pathological examination revealed fragmented and degenerated endometrial tissue without malignant changes. Breast tenderness was reported in nine patients (10.84%), all of which occurred during the first treatment year. One patient presented with recurrent breast discomfort, which resolved after the MHT regimen was adjusted from 2 mg/10 mg to 1 mg/10 mg. Gastrointestinal discomfort occurred in two patients (2.41%), both presenting during the early treatment phase with no subsequent recurrence. The notable AEs observed following MHT are depicted in Figure 2. Figure 2AEs reported post-MHT.A bar graph titled Adverse Events. The x axis lists categories: Unexpected bleeding, Breast tenderness, Gastrointestinal discomfort. The y axis label is Patients percent, ranging from 0 to 20 with tick marks at 0, 5, 10, 15, 20. Three vertical bars are shown with values printed above each bar: Unexpected bleeding 18.07, Breast tenderness 10.84, Gastrointestinal discomfort 2.41.A bar graph showing adverse events reported post M H T. AEs reported post-MHT. Changes in Uterine Fibroids Before and After MHT in Patients During Menopausal Transition LMM was used to compare annual follow-up data before and after medication to evaluate changes in the maximum cross-sectional area of uterine fibroids. The boxplot revealed a slight upward trend in fibroid cross-sectional area during the first four years of follow-up compared to baseline, whereas this trend turned downward by the fifth year (Figure 3). Longitudinal individual trend lines illustrate the distribution of fibroid area measurements collected at each follow-up year (Figure 4). Further detailed analysis of the linear mixed-effects model for fibroid cross-sectional area showed that statistical differences from baseline were observed in fibroid cross-sectional area over the first four years; however, these changes were small in magnitude and disappeared by the fifth year. (Table 2).Table 2Fibroid Cross-Sectional Area (Cm2) Changes Over TimeTime PointFibroid Cross-Sectional Area, cm2 Median (IQR)Estimate (vs. Baseline)P-valueIntercept-−2.550.087Baseline1.74 (0.78, 3.19)Year 11.96 (0.81, 3.59)0.600.0001Year 22.00 (0.82, 3.63)0.580.001Year 32.02 (0.86, 3.35)0.630.002Year 42.09 (1.04, 4.30)0.89<0.001Year 51.36 (0.91, 2.27)0.520.106Note: IQR: interquartile range. Estimate: regression coefficient vs. baseline from linear mixed-effects model. Figure 3Boxplot distribution of uterine fibroid cross-sectional area in the overall cohort.A boxplot showing uterine fibroid cross-sectional area across six groups: Baseline, Year 1, Year 2, Year 3, Year 4, Year 5. The y-axis label is Uterine Fibroid Cross-Sectional Area (cm superscript 2). The y-axis tick labels shown are 0, 5, 10, 15. The x-axis label is not shown; x-axis categories are Baseline, Year 1, Year 2, Year 3, Year 4, Year 5. Each category contains a box-and-whisker plot with overlaid individual data points. Baseline points extend from near 0 up to about 12 to 13. Year 1 includes points up to about 17. Year 2 includes points up to about 9. Year 3 includes points up to about 9 to 10. Year 4 includes points up to about 9 to 10. Year 5 includes points up to about 9 to 10. The median lines for all groups lie between about 1 and 3 on the y-axis, with Year 4 showing a higher upper whisker than the other years.A boxplot showing uterine fibroid cross-sectional area across baseline and yearly follow-up. Figure 4Linear mixed-effects model of longitudinal changes in uterine fibroid cross-sectional area Gray lines: individual patient trajectories; red line: overall trend line.A line graph with multiple trajectories showing uterine fibroid cross-sectional area over time. The horizontal axis label is Baseline, Year 1, Year 2, Year 3, Year 4, Year 5. The vertical axis label is Uterine Fibroid Cross-Sectional Area (centimeter superscript 2). The vertical axis shows labeled ticks at 0, 5, 10, 15. Many thin lines represent individual trajectories across Baseline to Year 5. A thicker overall trend line passes approximately through (Baseline, 2.0), (Year 1, 2.6), (Year 2, 2.6), (Year 3, 2.6), (Year 4, 2.9), (Year 5, 2.5). Individual trajectories include higher values reaching about 17 at Year 1 and about 12 at Baseline, with several lines around 9 to 10 at Years 1 to 4.A line graph showing longitudinal changes in uterine fibroid cross-sectional area over follow-up years. Table 2Fibroid Cross-Sectional Area (Cm2) Changes Over TimeTime PointFibroid Cross-Sectional Area, cm2 Median (IQR)Estimate (vs. Baseline)P-valueIntercept-−2.550.087Baseline1.74 (0.78, 3.19)Year 11.96 (0.81, 3.59)0.600.0001Year 22.00 (0.82, 3.63)0.580.001Year 32.02 (0.86, 3.35)0.630.002Year 42.09 (1.04, 4.30)0.89<0.001Year 51.36 (0.91, 2.27)0.520.106Note: IQR: interquartile range. Estimate: regression coefficient vs. baseline from linear mixed-effects model. Fibroid Cross-Sectional Area (Cm2) Changes Over Time Note: IQR: interquartile range. Estimate: regression coefficient vs. baseline from linear mixed-effects model. Boxplot distribution of uterine fibroid cross-sectional area in the overall cohort. Linear mixed-effects model of longitudinal changes in uterine fibroid cross-sectional area Gray lines: individual patient trajectories; red line: overall trend line. Discussion In this real‑world retrospective observational study, a total of 83 female patients aged 45 to 55 years were included, excluding those with early menopause and premature ovarian failure. As per MHT guidelines,12 therapy regimens were individualized based on symptom severity, treatment response, and patient preferences, with primary goals of regulating menstrual patterns, alleviating menopausal-related symptoms, and preventing osteoporosis. Changes in fibroid size were monitored throughout therapy to evaluate the clinical evidence regarding the safety of MHT. Previous studies suggested that fibroid growth is minimal or absent in postmenopausal women receiving appropriately selected hormone regimens.15,17,19 However, this cohort focused on the menopausal transition. According to the STRAW+10 criteria,20 this stage is characterized by declining ovarian reserve and substantial hormonal fluctuations. A 2001 review demonstrated that hormone therapy may result in fibroid enlargement without causing clinical symptoms,21 a concern that is still emphasized in current clinical guidelines.22 Among menopausal transition women receiving MHT, discernible differences in fibroid cross-sectional area were found in the first four years of treatment, which were no longer present at year 5. Considering the subtle changes in fibroids over time in this study, MHT can be safely used under routine monitoring if the lowest effective dose is adopted. That said, further prospective studies are needed to clarify the long-term effects of such fibroid changes. Although uterine fibroids are the most common benign gynecological tumors, their exact pathogenesis remains unclear. The prevailing theories include genetic predisposition, sex hormone abnormalities, and stem cell mutations. The 2017 Chinese Uterine Fibroid Expert Consensus noted that increased estrogen and progesterone secretion during pregnancy promote fibroid enlargement, and exogenous hormone replacement therapy can also lead to fibroid growth.23 One study have summarized the synergistic effects of estrogen and progesterone on fibroid cell proliferation.24 However, the limited studies conducted in untreated premenopausal women indicate that fibroid size and patient age are key variables, highlighting the difficulty of predicting fibroid growth on an individual basis.25 Prediction models suggest that age exerts a complex impact on fibroid growth, with the highest incidence observed between 30 and 50 years of age, and a tendency for fibroids to regress after age 50. These observations indicate that fibroid growth is influenced by multiple factors, and whether changes in fibroid size are absolutely correlated with sex hormones remains unclear. Furthermore, the study has confirmed that body mass index (BMI) and fibroid number are important factors influencing changes in fibroid size, And fibroids shrink more rapidly in the early postmenopausal period than in the late postmenopausal period, suggesting that menopausal status plays a pivotal role in fibroid size changes.26 A Chinese epidemiological study reported that in 2016, women aged 40–54 years accounted for 66.74% of all uterine fibroid cases in China, further indicating that the perimenopausal period represents a high-incidence age range for uterine fibroids.27 In the present study, all included patients were aged between 45 and 55 years during the special menopausal transition period, with the majority having a single fibroid (n=57; 68.67%) and the remaining patients having multiple fibroids (n=26; 31.32%). We adjusted for baseline age, fibroid number (solitary/multiple), baseline fibroid cross-sectional area and prior myomectomy history, which to some extent supports the credibility of our statistical findings. However, it must be acknowledged that the lack of adjustment for key factors such as BMI may limit the interpretability and generalizability of our results. The effect of estrogen supplementation on the size of fibroids has become a primary focus of research with most of the studies conducted in late menopause, often debating administration and drug types. In 1995, researchers reported that hormone therapy in perimenopausal women could stimulate cell proliferation, affecting uterine size and endometrial growth.28 In 1996, a study of 159 postmenopausal women examined the effects of transdermal estrogen combined with periodic oral medroxyprogesterone acetate on uterus over 6 to 12 months. The results showed a mild increase in uterine size, fibroid size, and endometrial thickness during the initial treatment period (especially within the first 6 months), which subsequently stabilized with prolonged treatment.29 Since 2000, several studies have explored the relationship between MHT and uterine fibroid changes in postmenopausal women.17,19 In postmenopausal women, oral estrogen-progestin therapy generally does not induce significant changes in fibroid size, whereas transdermal preparations may have a more pronounced effect.30 A study by Colacurci et al31 suggested that continuous hormone supplementation does not significantly increase postmenopausal fibroid volume; however, a very low resistance index (RI) was detected in the uterine arteries of some patients with fibroid growth, suggesting that RI may serve as a useful predictor of fibroid growth risk during MHT. Therefore, pre-treatment uterine artery RI is recommended as an ultrasound parameter for assessing fibroid growth potential. Furthermore, a Korean study found no significant difference in fibroid response based on the route of estrogen administration or the type of progestin used.15 Notably, most previous studies have focused on postmenopausal women, with very few addressing the menopausal transition period. This research gap likely reflects the unique characteristics of this transitional phase, namely declining but fluctuating hormone levels and systemic hormonal instability, which also represents a high-risk period for the development and progression of uterine fibroids. The present study fills this data gap in this specific population, suggesting that initiating MHT during this hormonally dynamic period is feasible with close monitoring. Fibroid size remains stable without any clinically significant changes. In light of existing literature, future efforts may attempt to develop clinical prediction models incorporating multiple relevant factors such as age, fibroid number, and ultrasound parameters (eg., RI) to help assess the risk of fibroid growth following MHT initiation. Furthermore, both the International Menopause Society (IMS) and the Chinese Menopause Group recommend individualized MHT for patients with uterine fibroids, excluding those who have clear surgical indications. For women in the menopausal transition, a sequential regimen is advised during the first year of therapy to minimize unintended bleeding.12,32 In this study, self-reported adverse events included unexpected bleeding (18.07%), breast discomfort (10.84%), and gastrointestinal discomfort (2.41%). Some patients with recurrent bleeding received regimen adjustments, and one case underwent further evaluation, with no endometrial malignancy identified. Breast discomfort and gastrointestinal symptoms generally resolved gradually with continued treatment. The relatively higher incidence of unexpected bleeding in this study might be attributable to the significant hormonal fluctuations in this age group (45–55 years). The 2024 Royal College of Obstetricians and Gynaecologists guideline notes that the incidence of unscheduled bleeding during MHT can be as high as 40%; however, not all such patients require urgent referral to a cancer center. Through detailed medical history taking, standardized follow-up, and appropriate medication guidance, individualized regimen adjustments based on menstrual status, fibroid size, and contraceptive needs can reduce unnecessary anxiety and invasive investigations in low-risk women.33 A study in 2004 indicated that among patients with irregular bleeding on MHT, the incidence of endometrial malignancy is extremely low, whereas benign polyps are relatively common (14%).34 A 2019 review proposed that most women with unscheduled bleeding on MHT may have no identifiable pathological cause; in the absence of risk factors or specific clinical concerns, rapid referral is unnecessary. Abrupt discontinuation of MHT may lead to worsened vasomotor symptoms, increased medical consultations, depressive symptoms, and reduced quality of life.35 Since sequential estrogen therapy in our study naturally induces regular withdrawal bleeding and gradually stabilizes the menstrual cycle in perimenopausal women, irregular or unexpected bleeding is common at the beginning of the therapy, especially in women who are still having some natural hormonal fluctuations. Therefore, on the basis of thorough pre-treatment evaluation, it is recommended that clinicians guide patients on appropriate MHT use, monitor endometrial status when indicated, and perform hysteroscopic evaluation when endometrial pathology is suspected. In this study, the incidence of breast discomfort was 10.84%. Some women reported breast discomfort during the initial stage of treatment (ie., the first year of follow-up), and these symptoms gradually resolved with continued treatment. Ideally, relevant breast follow-up data should be collected before treatment initiation and during annual health check-ups. However, the present study was unable to provide specific report descriptions or related breast grading. Recent reviews have indicated that the risk of breast cancer in women considering menopausal hormone therapy remains complex. Estrogen alone after hysterectomy does not increase the risk of breast cancer, whereas estrogen-progestin therapy may be associated with a modest increase in risk. Notably, currently used MHT formulations differ significantly from those tested in randomized controlled trials, and their safety profile is more favorable. Concurrently, treatment standards for breast cancer have been continuously updated, and patient mortality rates have substantially declined.36,37 These concepts are consistent with the 2023 Chinese guidelines on menopausal hormone therapy.12 Therefore, observation-based management of transient breast discomfort occurring early in treatment is feasible in this study. However, the availability of specific examination results would provide stronger support for this finding. This study has certain limitations. First, the retrospective observational design limits the ability to infer causal relationships between MHT and changes in fibroid size. Second, the sample size is small and limited to a single center, which may reduce the generalizability of the findings to broader populations. Third, ultrasounds were performed by different radiologists, which may have introduced variability in fibroid measurements and affected the consistency of imaging assessments. Fourth, we must acknowledge that the absence of a non-MHT control group, combined with the fact that the menopausal transition itself is characterized by considerable hormonal fluctuations and multiple influencing factors, and that fibroid size changes during this stage show substantial individual variability, precludes the determination of whether the observed changes in fibroid size are attributable to MHT, physiological fluctuations, or other confounding factors. Given that causal inference is not supported by the study design, the findings should be interpreted as associations rather than definitive therapeutic or protective effects. Therefore, large-scale, prospective, multi-center randomized studies with adequate sample sizes and control groups are warranted to further validate these findings. Conclusion This real-world study demonstrates that the estradiol/dydrogesterone sequential regimen induced small but statistically significant alterations in fibroid size during the initial four years of treatment, and such differences disappeared by the fifth year. These changes were marginal and did not result in clinically meaningful fibroid enlargement. Although irregular bleeding occurred during the initial phase, it was transient and self-limiting. Overall, these findings support the safety and clinical feasibility of this sequential therapy for women with uterine fibroids.